Shuttle Pharmaceuticals amends 8-K, says UDC merger not significant and financials not required

Reuters2026/08/17 21:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Shuttle Pharmaceuticals filed an amended 8-K to correct its earlier merger disclosure tied to the May 1, 2026 closing with United Dogecoin.
The amendment reclassifies the transaction as not reportable under Form 8-K Item 2.01, reversing the prior presentation as an acquisition.
It also withdraws the expected requirement to file UDC historical financial statements or pro forma financials, marking both as not applicable.
Management concluded UDC was not a “business” under ASC 805 at closing, so Regulation S-X Rule 3-05 and Article 11 financials were not required.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038786), on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Shuttle Pharmaceuticals amends 8-K, says UDC merger not significant and financials not required

You may also like

Crypto prices